Inflammatory Bowel Disease Drugs Market To Reach $9.3bn In 2019, A New Study Predicts

12 September 2018
Pharma

A new report by visiongain forecasts the world market for inflammatory bowel disease medicines will reach $9.3 billion in 2019. That revenue prediction and others appear in Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn’s Disease and Ulcerative Colitis. Visiongain, a business information publisher and consultancy in London, UK, published that study in January 2016.

Visiongain predicts that the IBD pharmaceuticals market will grow in revenues owing to the increasing use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions at present, they dominate the market for revenue generation and held 68% of the global IBD market in 2014. From 2016 that worldwide market will be stimulated by rising disease incidence and non-invasive diagnosis, as well as technological advances in medicines. That industry’s R&D holds promise.

Sandra Wenas, a senior pharmaceutical industry analyst in visiongain, said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to offset this loss.

“An increased use of biologics will be the main sales driver to 2026. As more doctors advocate the top-down therapy approach, and more studies justify the cost effectiveness of monoclonal antibodies for IBD, biological drugs’ revenues will expand and claim 57% of the IBD treatment market’s revenues by 2026. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”

Visiongain’s new analysis shows revenue forecasts to 2026 at overall world market, submarket, product and national level. First it forecasts five world-level submarkets:

• Biologics, including monoclonal antibodies (mAbs)
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators.

That investigation next predicts the revenues of 17 leading IBD drugs to 2026, including Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri, Cimzia, Entocort and recently approved treatments Uceris, Simponi and Entyvio.

Visiongain’s analysis includes trends and revenue predictions of 11 leading national markets to 2026:

• US
• Japan
• EU5:Germany, France, UK, Spain and Italy
• BRIC: Brazil, Russia, India and China.

The study also discusses research and development, including agents in these classes:

• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists.

That new report includes qualitative analyses and interviews with two authorities in that field. It also discusses leading companies: AbbVie, Janssen Biotech, Allergan and Shire Pharmaceuticals.

Inflammatory Bowel Diseases (IBD) 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostics and contract services.

Recent News

Visiongain Publishes Fill-Finish Manufacturing Market Report 2021-2031

Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.

02 September 2021

Read

Visiongain Publishes Epilepsy Therapeutics Market Report 2021-2031

As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.

24 August 2021

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2021-2031

From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.

24 August 2021

Read

Visiongain Publishes Bowel Management Systems Market Report 2021-2031

Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.

17 August 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever